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We developed a pharmacokinetic and pharmacodynamic model o f  warfarin 
absorption, metabolism, and anticoagulant action appropriate for guiding anti- 
coagulant therapy. The model requires only two independently adjustable 
parameters to describe warfarin's effect on individual patients. For any given 
individual, these parameters are rapidly and inexpensively identified using a 
computer program based on the model. Test data were generated by superimpos- 
ing Gaussian noise on dose-response curves calculated with the model. Then the 
computer program was applied to the test data. Future prothrombin complex 
activities (PCA "s) and maintenance doses were predicted accurately early in 
the course o f  drug administration. In addition, the program accurately predicted 
PCA response in two groups o f  normal volunteers. 
INTRODUCTION 
Oral anticoagulants such as sodium warfarin are used in the t reatment  of  
several serious disorders such as thrombophlebi t is  and pulmonary embolism, 
as well as following some types o f  cardiac surgery. The use of  these drugs is 
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complicated by wide variations in individuals' responses to anticoagulants, 
which can lead to periods of  underdosing and increased risk of thrombosis, 
or of  overdosing and increased risk of  hemorrhage. Although attempts have 
been made to estimate warfarin maintenance doses on the basis of  such char- 
acteristics as body weight (9), there is no simple laboratory test or physical 
measurement that will provide a reliable estimate of  a patient's maintenance 
dose prior to beginning treatment. Since the maximal effect on the pro- 
thrombin complex activity (PCA) of  a single warfarin dose occurs 36 to 54 h 
after the drug is given, the effects of  daily doses are cumulative and difficult 
to predict intuitively. 
Methods for initiating oral anticoagulation should minimize the time 
required to achieve steady-state PCA values within the therapeutic range 
(here considered to be 20% to 30% of  control), while protecting the patient 
from possible complications of  drug therapy. In attempting to achieve this 
goal, a wide variety of  approaches to initiating anticoagulation have been 
suggested. Initial doses have ranged from a very large (up to 60 mg) loading 
dose on the first day of  therapy to initial doses much nearer the expected 
maintenance dose (usually less than 10 mg/day). The diversity of  recom- 
mendations underscores the difficulty which the physician faces in initiating 
therapy with warfarin. Even after the more difficult initial anticoagulation 
has been achieved, most investigators have been able to maintain patients 
within the desired PCA range only 50% to 70% of  the time (1, 10, 14, 17). 
To more safely and systematically estimate the dose of  anticoagulant 
which should be given, several investigators developed theoretical models 
of anticoagulant physiology and computer  programs for assisting the clin- 
ician in prescribing proper warfarin doses (11, 15, 18, 20). Sheiner (18) 
modeled the kinetics of  warfarin absorption and elimination by the equation 
n 
Q(t)  = E C i exp[-ke(t-t/) l, (1) 
i= 1 
where 
Q ( t )  is the total body warfarin (mg), 
k e is the elimination rate constant for warfarin (day'X), and 
C i is the dose o f  warfarin (mg) given at time t i. 
The effect of  warfarin on the prothrombin complex activity P was described 
by the equations 
dP/dt = - k p P +  (1--sQ It])  S m 
dP/ dt = - kp P 
if 1-sQ[t ]  ~> 0andP < 100 
if 1- s Q [ t ] <  0orP  = 100, 
(2) 
where 
kp  is the prothrombin complex degradation rate constant (days-I), 
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S m is the maximum rate of prothrombin complex synthesis (percent/ 
day), and 
s is a sensitivity constant (mg-~). 
Theophanus (20) used the same model as Sheiner for warfarin absorption 
and elimination, but modeled the effect of  warfarin on the prothrombin 
complex activity as 
dP/dt = -S  m ln(Q/Qmax) - kpP, (3) 
where Qmax is a concentration of  warfarin which produces total inhibition 
o f  prothrombin complex synthesis. Both Sheiner and Theophanus incor- 
porated their models into computer  programs for predicting the response of  
patients to anticoagulant drugs. 
However, these models suffer from serious drawbacks. Although the 
expression used for the absorption and elimination of  the drug appears to 
be reasonable, the representations for the effect of  warfarin on prothrombin 
complex synthesis do not arise naturally from the known biochemical 
mechanism of  warfarin's effect. Sellers and Koch-Wesser (16) have suggested 
that inhibition of active prothrombin complex synthesis is best described 
by an enzyme-substrate model, and hence a Michaelis-Menten type of  
equation. This suggestion is consistent with the known mechanism of  
warfarin's act ion-compet i t ive inhibition of  the conversion of  descarboxy- 
prothrombin to prothrombin (19). In addition, Sheiner and Theophanus both 
postulate that there is a warfarin dose that completely inhibits prothrombin 
complex synthesis. One would not expect the existence of  such a maximum 
dose if prothrombin complex  synthesis is inhibited by a mechanism de- 
scribed by either a competitive or a noncompetit ive enzyme~ model. 
Furthermore, Theophanus'  model requires the existence of  a minimum 
effective dose, which is also unrealistic if warfarin acts as a competitive 
inhibitor. 
In this paper we present an alternative representation of  warfarin pharma- 
codynamics that corresponds more closely than models presented previously 
to the known physiologic systems. The model serves as the basis for an 
algorithm for computer-assisted anticoagulation that is simple enough to be 
implemented on a laboratory computer.  The algorithm requires only the 
patient's warfarin dosage and prothrombin response history. It 
1. identifies, using a nonlinear least squares method,  the important  
parameters determining the patient's response to sodium warfarin, 
2. predicts the patient's response to possible future doses of  the drug, 
3. suggests a dosage of  drug to be given the next day to achieve appro- 
priate levels of  anticoagulation, and 
4. gives a graphical display of the patient's responses to warfarin to date. 
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THE WARFARIN MODEL 
We assume that warfarin is administered orally at times tl,  t2, t3 9 . 9 
t n and is absorbed from the gastrointestinal tract into the circulation ac- 
cording to the equation 
dG/dt = -kgG + D(t) ,  
where 
D ( t )  = C i 6 ( t  - t i ) , i  = 1 , 2 . . . n ,  
6 ( t  - ti) is Dirac's delta function, 
C i is the dose (mg) of warfarin given at time ti, 
kg  is the rate constant for warfarin absorption (day-l), 
n is the total number of doses that have been given, 
G is the amount of drug in the gastrointestinal tract (mg). 
(4) 
The nongastrointestinal total body warfarin content Q should obey the 
equation 
dQ/dt  = kgG - keQ , (5) 
where k e is the warfarin elimination rate constant. 
Since the absorption of warfarin is very rapid, this model is essentially 
equivalent to that utilized by both Sheiner and Theophanus for warfarin 
absorption and elimination. Equations 4 and 5 may, however, also describe 
the pharmacokinetics of drugs which are not so rapidly absorbed, such as 
dicumeral. 
The prothrombinemic response to drug is given by 






is the free fraction of warfarin divided by the distribution volume 
(liter -1 ), 
is the maximal rate of  prothrombin complex synthesis (percent per 
day), 
is the prothrombin degradation rate constant (days "1), 
is a Michaelis constant (mg/1), and 
is the prothrombin complex activity (PCA). 
At time t = 0, Q ( t )  = G( t )  = 0 and P ( t )  = P0, the measured initial pro- 
thrombin complex activity. 
This equation differs considerably in both origin and effect from that used 
by previous workers (11, 15, 18, 20). It arises naturally from the assumption 
that warfarin exerts its effect by competitive inhibition of vitamin K utilized 
in the prothrombin carboxylation reaction. One need not assume values for 
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minimally or maximally effective concentrations of drug, and the equation 
is continuous for all drug concentrations. 
At time t = 0, there is no warfarin present (Q = 0) and the system is ex- 
pected to be at steady state. It follows from Eq. 6 that 
S m = kpP O. ( 7 )  
Since there is no evidence that the presence of warfarin changes the rate of 
prothrombin complex degradation under normal conditions, the factor 
kpPo may be substituted for S m in Eq. 6, yielding 
dP/dt = kpP 0 (1 - wQ/[wQ + kin] ) - kpP. (8) 
The sensitivity of the prothrombin complex activity, as given by Eq. 6, 
to the parameters kg, kp, k e, km, w, and P0 was tested by determining the 
behavior of P(t) for many combinations of the parameters. Analysis of the 
results indicates that the prothrombin response P(t) as given by the model 
is particularly sensitive to k e and k m over all ranges of P, and to P0 when 
P is large. P(t) is relatively insensitive to changes in kg, kp, and w, within 
the ranges normally found in patients anticoagulated with warfarin (10). 
This probably results less from the innate sensitivity of the model than it 
does from the fact that the inherent biological variability of the absorption 
rate constant kg, the binding constant w, and the initial prothrombin activity 
Po are low. Nevertheless, this has important consequences in the selection 
of a dosage recommendation algorithm, as it is clearly most important to 
assure rapid identification of the more important parameters, even if this 
means that no attempt is made to accurately identify the less important 
ones. We are thus able to reduce the complexity of the model by proceeding 
as follows: 
1. The value for P0 is measured before anticoagulation is begun. 
2. The constant kp is assumed to be 0.9/day, nearly the same as that 
found by Levy et al. (7). Hence 
S m -- 0.9P 0. (9) 
3. Since the value of kg has little importance, total warfarin content is 
estimated from Eq. 1 rather than from Eqs. 4 and 5. 
4. The constant w is assumed to be 0.01 (16). 
Thus only the two unknown parameters to which the model is particularly 
sensitive, k e and km, must be identified in order to predict response to anti- 
coagulants. This is advantageous, since these parameters can be identified 
more rapidly than they could be if a greater number of parameters were 
present. In addition, computation costs are reduced greatly. 
If kin, the Michaelis constant, represented simply the competitive inhibi- 
tion of a single prothrombin complex carboxylation enzyme, it might not 
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be expected to vary from patient to patient. This parameter varies con- 
siderably among patients since it represents inhibition of  several enzymatic 
processes, and is also affected by transport of  warfarin into the compartment  
where prothrombin complex is synthesized. 
IMPLEMENTATION OF THE MODEL 
Implementation of  the model for the purposes of predicting anticoagulant 
response and recommending warfarin doses is accomplished easily. Equa- 
tion 1 is used without modification. Thus, given Q(t) ,  Eq. 8 may be inte- 
grated numerically in any of  a number of  ways. Although several methods 
were investigated, the backward Euler integration, 
Yi+ 1 = Yi + h f ( Y i +  1,ti+ 1 )' (10) 
where 
Yi is our approximation to P(ti)  , 
t i+l  = ti + h ,  
h is the step size, and 
f i s  the expression for dP/d t  (from Eq. 8), 
was chosen because it was found to be reliable in the regions of  the system 
corresponding to rapid decay of  P (3). In addition it was capable of  giving 
the required accuracy with extremely low computational costs. Roundoff  
error, which is the method's  biggest liability, is not expected to accumulate 
sufficiently to affect adversely the overall performance during the time 
periods considered. Other integration methods could be employed, but  
would increase the computational expense without  a clinically significant 
increase in accuracy. 
We investigated several approaches to the parameter identification prob- 
lem. Nonlinear Kalman filtering (4), for instance, may be used to estimate 
the patient's pharmacodynamic parameters while providing an estimate of  
their reliability. Maximum likelihood parameter estimation is potentially a 
viable alternative to the least squares approach. The patient parameters 
may generally be identified with greater precision using quite sophisticated 
iterative methods (5), nonlinear least squares methods (2), or Simplex (8) 
methods. 
To minimize cost and to obtain increased flexibility in implementing 
the algorithm on minicomputers or microprocessors, we have adopted the 
following simple parameter identification procedure which is computational- 
ly less expensive than any of  the above, and which, in spite of  its great 
simplicity, is sufficiently accurate for clinical application. 
Ten possible values of k e and ten possible values of  k m are examined 
(Table 1). For each pair which is capable of yielding clinically reasonable 
maintenance doses (approximately fifty pairs), Eqs. 5 and 8 are integrated 
with the starting values 
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TABLE 1. Values for the Elimination Rate Constant k e and the Michaelis Constant k m 
Considered by the Parameter Identification Procedure 
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El iminat ion Rate Constant  k e Michaelis Constant  k m 











Q(t = o) = 0 
P(t = 0) = P0 (measured). 
The appropriate values of k e and k m for the patient under consideration 
are selected by minimizing the nonlinear least squares function 
]2 
R = ~ ~2 i _ P(ti ) / (p.)2, (11) 
i=1 
where the P i ' s  are values for the prothrombin complex activity measured 
at time t i, and P ( t  i) is the value for P obtained by integrating Eqs. 1 and 8. 
The use of Pi in the denominator of Eq. 1 1 is appropriate if the standard 
deviations of the measurements Pi are a constant fraction of P. This appears 
to be approximately true over much of the range of P. The weighting factors 
~2 i are given by 
~i = (1/z)i-1 (12) 
for a chosen value of z between 0 and 1. This is equivalent to a time- 
exponential weighting in which the most recent measurements are weighted 
most heavily. Exponential weighting compensates for gross measurement 
errors, differences between the model and the physiologic system, and for 
changes in the patient's physiologic status after anticoagulation is begun. 
DOSAGE SELECTION 
After the values of k e and k m have been found, they may be used to 
predict patient response to a given dose of warfarin simply by integrating 
the above equations. They may also be used to suggest dosages for future 
days. 
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TABLE 2. Maximum Dose of Warfarin That Can Be Recommended by the Program 







A rather simple approach to the dosage selection problem is taken. The 
maintenance dose required to keep the PCA as near to 25% as possible 
has been estimated in advance for all allowed combinations of the param- 
eters k e and kin ,  and is selected from a dosage table in the program once 
k e and k m have been determined. The selected dose is intended to min- 
imize the likelihood of the patient's prothrombin complex activity going 
outside the therapeutic 20% to 30% range once it has first been achieved, 
to minimize the number of dosage adjustments required during the course 
of anticoagulation, and to keep the time required to achieve anticoagulation 
acceptably low. 
To be certain that only clinically useful dosages are profferred, dosages 
are restricted to amounts which can be given as a combination of 1.0 and 
2.5 mg units. Since there is no advantage to using a loading dose, and since 
our experience suggests that the fmal maintenance dose for an average 
patient is likely to be about 5 mg/day, the dosage recommendation algo- 
rithm incorporates the restrictions shown in Table 2 on the maximum daily 
dose that the program may recommend. These limitS are intended to min- 
imize the risk of overanticoagulating a patient who actually requires a low 
loading and maintenance dose. 
We have previously investigated more sophisticated approaches to dosage 
optimization. The objective for these optimization problems was to min- 
imize the time required to first achieve a therapeutic PCA; the dosages 
recommended were constrained such that the predicted response did not go 
outside the therapeutic range after once achieving it. The difficulties with 
this approach were that the patient's pharmacodynamic parameters k e and 
k m were not identified with sufficient accuracy early in the course of 
therapy to make the recommendations during the early initial phases 
reliable, and that the dosage schedules calculated were clinically unac- 
ceptable as a result of  the odd amounts of  drug recommended (for example, 
3.3 mg). 
TEST OF THE PARAMETER IDENTIFICATION PROCEDURE 
In order to gain an understanding of the speed and accuracy of the non- 
linear least squares parameter identification procedure, the following test 
was carded out: 
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1. An initial prothrombin complex activity P0 and constants k e and 
k m were selected. The appropriate "maintenance dose" was obtained 
from the dosage table and the response that would be expected if 
this dose were given every day from the start of therapy was calcu- 
lated from the model. In this way an "ideal patient" response was 
calculated. 
2. To simulate the effects of system and measurement noise, Gaussian 
random noise was superimposed on the response obtained above. 
For any given PCA, the standard deviation a of  this noise was given 
by a = oa ~ for a = 0.05, 0.10, 0.15, 0.20, and 0.25. The points thus 
obtained, which represent the expected laboratory measurements of 
prothrombin complex activity for such a "patient," are referred to 
below as "PCA responses generated by the model." 
3. The least squares identification procedure was employed, using the 
"noisy" data generated as described above, to find the "patient 
parameters" day to day. These parameters were then used to predict 
the "patient's" future responses to warfarin, referred to in Figs. 1 
and 2 as PCA responses "predicted by the program." 
In this way it was possible to determine how well the parameter identifica- 
tion procedure would function in the situation where the model describes 
exactly the physiologic response to warfarin, but where the data contain 
random noise resulting from changes in the "patient's" physiologic state as 
well as errors in the assessment of  the PCA. The results obtained for some 
typical simulations are shown in Figs. 1 and 2. As expected, the predictions 
are much more accurate and parameter identification much more rapid 
when the system noise is small than when it is large, emphasizing the need 
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FIGURE 2. PCA responses generated by the model and predicted by the program for a simulation 
having a system noise level o = 0.015P, elimination rate constant k e = 1.0 day -z , and Michaelis 
constant k m = 0.025 mg/I. 
for accurate and precise prothrombin activity measurements, particularly 
early in the course of therapy. Such measurements are seldom available. 
It was found that the quantity [Pi + P(ti)] [2, where Pi is the measured 
prothrombin complex activity and P(t i) is the a posteriori estimate of the 
activity (from the model) provides a better estimate of the true activity (in 
this model system) than either Pi or P(ti) alone. The computer program 
makes this additional information available to the Clinician, although we 
have no basis to assert that this estimate is superior to the measured pro- 
thrombin complex activity in clinical usage. 
The simulations further substantiated the finding of the sensitivity analy- 
sis that errors in the initial estimate P0 are important in the initial phase of 
anticoagulation (when P is large) but not later on. Finally, the analysis 
confirmed that the simple parameter identification procedure outlined 
earlier is sufficient to give reasonable predictions of the prothrombin 
complex response to oral anticoagulants, providing the model is valid and 
the measurement noise not excessive. 
These simulations enable us to estimate the accuracy of predictions 
based upon the model, provided we can obtain an estimate for the system 
noise. In the following section we estimate this noise level based upon data 
from normal volunteers receiving constant doses of warfarin. 
ESTIMATING THE SYSTEM NOISE 
A model such as the one we have presented above is necessarily an ap- 
proximation, as we use only a single variable, the prothrombin complex 
activity, to quantify the effects of  warfarin on a very complicated clotting 
system in which a minimum of four clotting factors (Factors II, VII, IX, 
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and X) are affected by the presence of warfarin. In addition to this dif- 
ficulty there are errors in.the assessment of patient clotting status by PCA 
which complicate parameter identification and dosage estimation. These 
seemingly random errors we designate by the term "noise" together with 
fluctuations arising from such diverse sources as variation of the patient's 
body temperature, changes in the times at which warfarin is given and the 
PCA measured, and variation in the intervals between the time blood is 
drawn for PCA assessment and the time the laboratory test is performed. 
This short list is merely illustrative, and many other possible sources of noise 
exist. Data from a previous study (13) suggest that it is reasonable to con- 
sider this noise as Gaussian. 
As suggested in the discussion above, a more detailed understanding of 
the effects of system noise on the rapidity with which parameter identifica- 
tion may be accomplished is important to ascertain the results which can 
be expected from, and the range of clinical applicability of, the pharma- 
codynamic model. We have previously estimated the intrinsic measurement 
noise of the Quick one-stage test to be over 5% of the measured PCA (15). 
We have no a prior i  estimate for the magnitude of other contributions 
to the system noise, so only by a direct measurement can an overall estimate 
be obtained. The strategy used for this was as follows: From the values 
of the kinetic parameters k e and k m we have found in most patients, it 
seems likely that patients who have no physiologic instabilities and are 
receiving a constant dose of  drug will reach a steady-state PCA by the 
end of ten days of anticoagulation. If this is true any variation in pro- 
thrombin complex activities found after ten days may be attributed to 
system noise. Thus we estimated the total noise as the standard error of  all 
measurements taken after ten days, using data obtained in a previous study 
(13) in which normal volunteers received constant doses of warfarin for 
several weeks. There were six days available in the appropriate time range 
for each person in the data set. The mean PCA range for these ten patients 
ranged from 15% to 48%, and the noise thus calculated for each of the ten 
patients above, ranged from 10% to 20% of the prothrombin complex 
activity. Clearly, noise of this level limits our ability to identify accurately 
the pharmacodynamic parameters and predict prothrombin complex 
response to warfarin early in the course of therapy. 
STUDIES OF PROGRAM EFFECTIVENESS IN PREDICTING 
PATIENT RESPONSE TO SODIUM WARFARIN 
To evaluate the accuracy and effectiveness of the model of warfarin 
metabolism and action in predicting patient response to oral anticoagulants, 
a number of tests were performed using retrospectively obtained data. The 
first analysis was undertaken using data from O'Reilly and Aggeler (12), 
in which the same persons were, on different occasions, given both a large 
loading dose of sodium warfarin and several days of warfarin anticoagula- 
tion with much smaller doses (10 or 15 mg). A typical example of the 
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program's performance in predicting response to the bolus is shown in 
Fig. 3. The same subject's response to smaller daily doses is shown in Fig. 4. 
It is seen that in both cases satisfactory predictions of  response are made 
after several days of  warfarin administration, and that  a p o s t e r i o r i  least 
squares fits o f  the model  to the patient data are good. For a given subject, 
there may be considerable differences between the values for the pharma- 
cokinetic parameters k e and k m obtained after the single loading dose as 
compared to the values after multiple dosing. Although this finding may 
reflect differences in the pharmacokinetics and pharmacodynamics of  the 
drug at high and low concentrations, it more  likely reflects the effects of  
noise on the parameter  identification procedure.  If, instead o f  at tempting 
to identify both k e and k m from the dosage response data, one sets k e = 
0.25, the k m values are identified more  rapidly, and converge to the same 
values whether  the data is obtained after a large loading dose or a series o f  
smaller maintenance doses. This appears to reflect the lack o f  significant 
(from the standpoint of  this model)  interindividual biologic variability 
of  k e .  
The performance of  the program was also evaluated in a number  o f  normal 
volunteers Who were given 7.5 mg Of sodium warfarin each day for fourteen 
days (13). Although a somewhat longer time was required for adequate 
parameter identification, probably as a result of  higher system noise, both  
predictions and retrospective fits, as illustrated in Figs. 5 and 6, are good. 
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given 10 mg warfarin daily for 6 days (retrospective study). The "least squares PCA'" was calculated 
using the pharmacodynamic parameters identified on day 6. 
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Finally, as a test of  how well the program would perform in real patients 
in whom dosages vary from day to day and who might be expected to have 
somewhat less stable physiologic systems, a similar analysis was performed 
using data obtained from the hospital records of patients treated for a 
variety of  medical and surgical conditions. Again the program performed 
adequately in most cases, as illustrated in Figs. 7 and 8. 
Occasionally during the course of  anticoagulation, the pharmacokinetic 
and pharmacodynamic parameters identified for an individual patient would 
change fairly drastically (see, for example, Fig. 9). In general this change of  
pharmacokinetic parameters was insignificant from the standpoint of  mainte- 
nance dose estimation; the model  appeared to fit the data reasonably well 
with either set of  parameters (Fig. 10), and to make reasonable predictions 
of  future PCA measurements. The reason for the difficulty in parameter 
estimation appears to be the inherently ill-posed nature of  the parameter 
estimation problem for systems having equations reflecting Michaelis- 
Menten kinetics (21). Dose-response curves for markedly different param- 
eter combinations are very nearly the same. This difficulty could be 
overcome by measurement of  plasma warfarin concentrations. 
DISCUSSION 
We have presented a model of warfarin absorption, metabolism, and 
action which conforms well to known biochemical mechanisms of  action 
and which can be used to predict accurately the response to warfarin once 
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enough PCA and dosage data have been obtained. We believe the model  
to be more realistic than those presented by previous investigators. Only 
two parameters need be identified, using exceedingly simple and inexpensive 
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FIGURE 9. Values for the pharmacodynamic parameters identified by the program for "simulated 
patient" shown in Fig. 2. (a) Elimination rate constant k e. (b) Michaelis constant km. 
computational procedures, to predict accurately patient responses to the 
drug. Although the program's effectiveness in guiding therapy may be 
degraded if system noise levels are too high, we believe that it may be an 
effective and useful aid in guiding anticoagulant therapy in patients with 
a wide variety of medical and surgical problems. 
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The first parameter set is k e = 1,0 day-1 and k m = 0.025 mg/I, The second parameter set is k e = 
0,50 day -1 and k = 0.075 mg/I. 
Although a number of persons have reported the results of  studies in 
which computer programs have been used to assist in long-term anticoagula- 
tion (6, 22), none has investigated whether patients anticoagulated with 
computer  assistance remain within the therapeutic range for any greater 
percentage of the time than patients anticoagulated in the traditional way. 
The results of  the retrospective investigation reported here were sufficiently 
encouraging that we have undertaken a prospective study of  the program's 
effectiveness in guiding the initial phases of  anticoagulation. 
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